Parameter
| Biomarker | Tumor Mutational Burden (TMB) | Full name | Tumor Mutational Burden | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Predicting response to immunotherapy | ||
| Disease | Hepatocellular Carcinoma (HCC) - | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Tumor tissue/ctDNA (NGS) | ||
| Pathobiological Mechanisms | The total number of non-synonymous mutations in the tumor genome, high TMB can produce more neoantigens | ||||
| Clinical Availability Status | Study validation: The incidence of high TMB in HCC is low, and its value as a predictor alone is limited | ||||
| Notes and Dynamics | The combination of TMB and TILs can improve the accuracy of ICIs efficacy prediction | ||||